Overview

Thermo Fisher Scientific is an American life-science and clinical-research company headquartered in Waltham, Massachusetts. It was created in 2006 through the stock-for-stock merger of Thermo Electron and Fisher Scientific, bringing together an analytical-technology manufacturer and a major distributor of laboratory equipment, chemicals, supplies, and services. The combined company has developed into a broad supplier to pharmaceutical and biotechnology companies, hospitals, universities, government laboratories, clinical laboratories, industrial customers, and research institutions worldwide. The company operates through a portfolio of businesses and brands rather than a single product line. Thermo Scientific covers analytical instruments, laboratory equipment, chromatography, mass spectrometry, electron microscopy, and related software. Fisher Scientific is a distribution and procurement platform for laboratory products. Applied Biosystems supplies molecular biology, PCR, genetic-analysis, and sequencing technologies, while Invitrogen and GIBCO are associated with reagents, cell culture, and life-science research. Other important businesses include Patheon and PPD, which provide contract development, manufacturing, and clinical-research services; Nalgene, which supplies laboratory plasticware; and Olink, which provides advanced proteomics technologies. Thermo Fisher’s growth strategy has relied heavily on acquisitions that extend its scientific capabilities and increase its exposure to recurring consumables, clinical development, bioprocessing, and outsourced services. Notable transactions include Dionex, Phadia, Life Technologies, Alfa Aesar, Affymetrix, FEI, Patheon, Brammer Bio, PPD, PeproTech, The Binding Site, CorEvitas, and Olink. These acquisitions expanded the company from an instrument and laboratory-supply business into an integrated provider spanning discovery research, molecular diagnostics, biopharmaceutical development and manufacturing, clinical trials, and specialized laboratory services. Its products and services support workflows such as sample preparation, nucleic-acid extraction, PCR, DNA and RNA sequencing, mass-spectrometric analysis, chromatography, cell culture, protein research, bioprocessing, clinical testing, and pharmaceutical manufacturing. During the COVID-19 pandemic, Thermo Fisher received United States emergency authorization for a SARS-CoV-2 test and expanded manufacturing and supply activities connected with testing and vaccine production. It also worked with biopharmaceutical customers, including Pfizer and Moderna, on mRNA-related development and manufacturing activities. The company’s positioning combines high-value scientific instruments with consumables, reagents, software, distribution, and long-term service relationships. This breadth allows it to serve both research and regulated production markets, although it also exposes Thermo Fisher to antitrust review, healthcare regulation, export controls, and ethical questions concerning the use of genetic-analysis technologies. Marc N. Casper has led the company as chief executive since 2009 and became board chair in 2020. Thermo Fisher remains an active, publicly traded global supplier whose business spans life-science tools, clinical research, diagnostics, laboratory products, and pharmaceutical services.

History

Thermo Fisher Scientific combines two major historical lineages in laboratory science. Thermo Electron was co-founded in 1956 by George N. Hatsopoulos and Peter M. Nomikos. It developed analytical and laboratory technologies, eventually building businesses around measurement, analysis, and scientific instrumentation. Fisher Scientific traced its origins to 1902, when Chester G. Fisher established a Pittsburgh laboratory-supply company. Fisher grew as a supplier and distributor of laboratory equipment, chemicals, consumables, safety products, and related services for scientific, medical, educational, and industrial customers. The two companies announced a tax-free, stock-for-stock merger on May 8, 2006. The transaction was completed on November 9, 2006, creating Thermo Fisher Scientific Inc. The combined company was headquartered in Waltham, Massachusetts, traded on the NYSE under TMO, and initially represented approximately $9 billion in combined revenue and about 30,000 employees. The strategic logic was to unite Thermo's analytical-instrument capabilities with Fisher's broad laboratory-supply and distribution network. After the merger, Thermo Fisher pursued an acquisition-led expansion strategy. The company acquired Dionex in 2010, strengthening chromatography and ion-analysis capabilities, and Phadia in 2011, expanding allergy and autoimmune diagnostics. In 2013 it acquired Life Technologies after competing with Roche, adding major businesses in genetic analysis, sequencing, cell culture, molecular biology, and research reagents. Subsequent acquisitions included Affymetrix and FEI in 2016, extending the company's reach into microarray analysis, electron microscopy, materials science, and structural biology. The company continued to expand its biopharmaceutical and manufacturing activities. It acquired Patheon in 2017, adding contract development and manufacturing services for pharmaceutical and biotechnology customers. In 2018, BD's Advanced Bioprocessing business added further bioprocessing products and technologies. These transactions complemented Thermo Fisher's instruments and consumables with services that support the development and production of medicines. The acquisition of PPD, completed in 2021, was one of the company's most significant steps into clinical research services. PPD added contract research capabilities covering clinical trials and related services for biopharmaceutical and biotechnology customers. The deal broadened Thermo Fisher's value proposition from supplying laboratories and bioprocessing facilities to supporting drug developers through clinical development. Thermo Fisher was also a major supplier during the COVID-19 pandemic. Its PCR instruments, molecular reagents, sample-collection materials, and laboratory supplies were used by testing laboratories and healthcare systems. The period highlighted the importance of the company's manufacturing scale and distribution infrastructure, while also reinforcing its exposure to demand cycles in diagnostic testing. In 2023, Thermo Fisher completed the acquisition of The Binding Site, a specialty-diagnostics company known for assays and systems used in immune-disease and multiple-myeloma testing and monitoring. In 2024, it completed the acquisition of Olink, bringing next-generation proteomics technology into the Life Sciences Solutions segment. These additions supported the company's broader strategy of combining instruments, reagents, data, diagnostics, and services across research and healthcare workflows. Thermo Fisher's present structure is therefore the result of continual consolidation across laboratory supply, analytical measurement, genomics, proteomics, diagnostics, clinical research, and biopharmaceutical manufacturing. Its business is organized around a house of specialized brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Gibco, Unity Lab Services, PPD, and Olink. Marc N. Casper became chief executive in 2009 and chairman in 2020. The company continues to operate as a public global supplier to scientific, medical, pharmaceutical, biotechnology, and industrial customers.

2024
Olink is acquired
[5]Thermo Fisher Scientific completes acquisition of Olinknasdaq.com
Olink's next-generation proteomics solutions become part of Thermo Fisher's Life Sciences Solutions segment.
2023
The Binding Site is acquired
[4]Thermo Fisher Scientific completes acquisition of The Binding Sitebusinesswire.com
Thermo Fisher expands specialty diagnostics for immune disorders and multiple myeloma.
2021
PPD is acquired
[2]Thermo Fisher Scientific completes acquisition of PPDprnewswire.com
The acquisition adds global clinical-research and clinical-development services.
2017
Patheon is acquired
[3]Thermo Fisher Scientific completes acquisition of Patheonprnewswire.com
Thermo Fisher adds contract development and manufacturing services for pharmaceutical and biotechnology customers.
2016
Affymetrix and FEI are acquired
[1]Thermo Fisher Scientificen.wikipedia.org
These acquisitions broaden the company into microarray analysis, electron microscopy, materials science, and structural biology.
2013
Life Technologies is acquired
[1]Thermo Fisher Scientificen.wikipedia.org
The transaction adds major genomics, sequencing, cell-culture, and molecular-biology capabilities.
2011
Phadia is acquired
[1]Thermo Fisher Scientificen.wikipedia.org
The acquisition expands Thermo Fisher's allergy and autoimmune-disease testing business.
2010
Dionex is acquired
[1]Thermo Fisher Scientificen.wikipedia.org
Thermo Fisher announces the acquisition of Dionex, expanding its chromatography and analytical-instrument portfolio.
2006
Thermo Fisher Scientific is formed
[7]Thermo Fisher Scientific is formedbiospace.com
Thermo Electron and Fisher Scientific complete their merger, creating Thermo Fisher Scientific and beginning trading under TMO.
1956
Thermo Electron is founded
[1]Thermo Fisher Scientificen.wikipedia.org
George N. Hatsopoulos and Peter M. Nomikos co-found Thermo Electron, an analytical and laboratory-technology company.
1902
Fisher Scientific is established
[1]Thermo Fisher Scientificen.wikipedia.org
Chester G. Fisher establishes the predecessor company that develops into a major laboratory-supply and scientific-distribution business.

Products and positioning

A scaled, integrated partner for science and healthcare, combining laboratory products, analytical platforms, diagnostics, digital tools, technical services, clinical development, and biopharmaceutical manufacturing support.

Analytical instruments and laboratory systems
Thermo Scientific
Thermo Scientific is the company's principal instrumentation and laboratory-technology brand. Its portfolio covers analytical measurement, mass spectrometry, chromatography, sample preparation, laboratory equipment, storage, monitoring, and connected workflow systems used in research, diagnostics, industrial laboratories, and biopharmaceutical production.
Genetic analysis and molecular biology
Applied Biosystems
Applied Biosystems provides PCR, real-time PCR, genetic-analysis, sequencing, and associated reagent systems. Its technologies are used in research, translational science, clinical testing, forensic analysis, and applications requiring amplification or characterization of nucleic acids.
Life-science reagents and research products
Invitrogen
Invitrogen supplies molecular-biology reagents, antibodies, proteins, transfection products, assay components, and laboratory kits. The brand supports workflows in cell biology, genomics, proteomics, immunology, and pharmaceutical research.
Laboratory distribution and supplies
Fisher Scientific
Fisher Scientific is Thermo Fisher's major distribution and procurement brand. It offers laboratory chemicals, consumables, equipment, safety products, production supplies, and healthcare materials from Thermo Fisher and third-party manufacturers.
Cell culture and bioprocessing
Gibco
Gibco provides cell-culture media, sera, supplements, reagents, and bioprocessing materials used in academic research, biotechnology, cell and gene therapy, vaccine development, and biologics manufacturing.
Proteomics
Olink
Olink develops next-generation proteomics solutions based on highly multiplexed protein analysis. Its products support biomarker discovery, translational research, precision medicine, and studies of complex biological systems.

Controversies

2021
Lacks estate sues Thermo Fisher Scientific over HeLa cells
The estate of Henrietta Lacks sued Thermo Fisher Scientific, alleging that the company continued commercializing results derived from HeLa cells taken without Lacks' knowledge or consent. The lawsuit seeks the company's net profits from commercialization and an injunction against use of the cells without the estate's permission; the allegations are not presented as a court finding.
Source
2021
Henrietta Lacks estate sues over HeLa cells
The estate of Henrietta Lacks filed litigation seeking compensation connected with the alleged unauthorized commercial sale and use of HeLa cells, which originated from Lacks without her consent.
Source
2021
HeLa-cell litigation by the Henrietta Lacks estate
The estate of Henrietta Lacks sued Thermo Fisher in connection with the alleged unauthorized commercial sale and use of HeLa cells. The dispute concerns the historical removal and commercialization of Lacks’s cells without her consent and broader questions about biomedical benefit-sharing and informed consent.
Source
2020
Reports question use of Thermo Fisher equipment in genetic surveillance
Reports and advocacy investigations alleged that Thermo Fisher equipment and related technologies were used by Chinese security authorities in genetic-surveillance activities involving ethnic minorities.
Source
2019
Cessation of sales in Xinjiang and genetic-surveillance allegations
Thermo Fisher announced that it would stop selling equipment in Xinjiang. Subsequent reporting and investigations alleged that company equipment and related technologies were used by Chinese security authorities in genetic-surveillance programs involving Uyghur, Tibetan, and Hui populations. Reports later questioned whether equipment continued to reach police users despite restrictions. The company also halted sales of DNA-collection kits in Tibet after further reports.
Source

Marketing campaigns

2020Connections for Life
Global · Biopharmaceutical research · Cell and gene therapy
A Gibco-centered campaign presented scientific work as a connection among ideas, cures, people, and careers. It highlighted researchers and healthcare workers contributing to work on coronavirus, cancer, genetic disease, and other conditions, while explaining the role of Gibco products in enabling research.
Outcome. The campaign helped broaden awareness of Gibco's role and was recognized in a business-to-business marketing case study for customer insight and advocacy.
Source
Pharma Services human-outcomes campaign
Pharmaceutical services · Biotechnology
A print and content campaign for Thermo Fisher's Pharma Services business used scientists, patients, and family members to illustrate the human consequences of drug-development work. Its messaging emphasized customized development and delivery support and challenged the perception that the company worked only with the largest pharmaceutical companies.
Outcome. The reported creative objective was to humanize the business, foreground scientific passion, and communicate that its services were relevant to a broader range of pharmaceutical and biotechnology customers.
Source
The Art of Cells
Global · Life-science research
This creative program invited cell scientists to describe their research and personal connection with cells. The resulting content used scientists' own perspectives to make cell biology more personal and accessible.
Outcome. The program produced a digital experience featuring twelve cell scientists and supported a more emotionally driven presentation of life-science research.
Source
Employee advocacy on LinkedIn
Global · Recruitment · Business-to-business marketing
Thermo Fisher used a LinkedIn employee-advocacy program to distribute company and employment content through employees' professional networks. The initiative initially focused on talent acquisition and later supported coordination between marketing, sales, and other internal teams.
Outcome. The program was described as generating benefits beyond recruitment, including greater internal alignment and commercial amplification.
Source
Unity Lab Services social lead-generation program
Global · Laboratory services
Working with Unity Lab Services, an agency-managed program combined organic LinkedIn content with paid media. The campaign structure was developed to move beyond awareness and support website engagement and lead generation.
Outcome. The reported objective was to increase engagement and qualified leads while aligning Unity Lab Services communications with wider corporate initiatives.
Source

Brand decisions

2024
Acquire OlinkM&A
Background
Olink's proteomics platform was considered complementary to Thermo Fisher's mass spectrometry and life-science offerings.
Action taken
Thermo Fisher completed the acquisition of Olink and placed it within the Life Sciences Solutions segment.
Aftermath
The transaction strengthened Thermo Fisher's position in multiplexed protein analysis and precision-medicine research.
Transaction value. Approximately US$3.1 billion, net of acquired cash (2024 transaction)
Source
2023
Acquire The Binding SiteM&A
Background
Thermo Fisher identified specialty diagnostics, including multiple-myeloma monitoring, as complementary to its existing diagnostics portfolio.
Action taken
The company completed the all-cash acquisition of The Binding Site for approximately £2.3 billion, or $2.8 billion at the referenced exchange rate.
Aftermath
The Binding Site joined the Specialty Diagnostics segment.
Transaction value. Approximately £2.3 billion or US$2.8 billion (2023 transaction)
Source
2021
Acquire PPDM&A
Background
The acquisition was intended to strengthen Thermo Fisher's pharmaceutical-services proposition with clinical research and development capabilities.
Action taken
Thermo Fisher completed the acquisition of PPD for $17.4 billion.
Aftermath
PPD expanded Thermo Fisher's role in clinical development and increased its integration with biopharmaceutical customers.
Transaction value. US$17.4 billion (2021 transaction)
Source
2017
Acquire PatheonM&A
Background
Thermo Fisher wanted to add pharmaceutical development and manufacturing capabilities to its laboratory and bioprocessing businesses.
Action taken
The company completed the acquisition of Patheon for approximately $7.2 billion.
Aftermath
Patheon became part of the Laboratory Products and Services segment and expanded Thermo Fisher's CDMO offering.
Transaction value. Approximately US$7.2 billion (2017 transaction)
Source
2013
Acquire Life TechnologiesM&A
Background
Thermo Fisher sought to expand in genetic analysis, sequencing, molecular biology, and cell culture.
Action taken
It acquired Life Technologies following a competitive bidding process.
Aftermath
The transaction materially broadened Thermo Fisher's genomics and life-science portfolio.
Transaction value. US$13.6 billion (2013 transaction)
Source
2006
Merge Thermo Electron with Fisher ScientificM&A
Background
Thermo Electron had strong analytical-instrument capabilities, while Fisher Scientific had a broad distribution and laboratory-supplies business.
Action taken
The companies completed a tax-free, stock-for-stock merger and operated under the Thermo Fisher Scientific name.
Aftermath
The merger created a large integrated supplier serving laboratory, healthcare, research, and industrial customers.
Source

Recent events

2026-08-12
Astorg completes acquisition of Thermo Fisher Scientific's microbiology business[12]Astorg完成对Thermo Fisher Scientific微生物业务的收购finanznachrichten.de
Reported: 2026-08-12
Astorg, a pan-European private equity firm, announced the completion of its acquisition of the global microbiology business from Thermo Fisher Scientific. The business now operates as an independent company led by CEO Dirk Bontridder and plans to launch under a new corporate brand later in 2026.
2022-10-31
Thermo Fisher announces agreement to acquire The Binding Site Group[13]赛默飞世尔宣布收购The Binding Site Group的协议finanznachrichten.de
Reported: 2022-10-31
Thermo Fisher announced a definitive agreement to acquire The Binding Site Group from a shareholder group led by Nordic Capital in an all-cash transaction valued at £2.25 billion, or $2.6 billion. Completion was expected in the first half of 2023, subject to customary closing conditions, including regulatory approvals.
2022-01-18
Olaris and Thermo Fisher partner to evaluate transplant diagnostic[14]Olaris与赛默飞合作评估移植诊断工具prweb.com
Reported: 2022-01-18
Olaris announced a partnership with Thermo Fisher Scientific to evaluate a metabolomics-based diagnostic for assessing kidney transplant recipients’ risk of complications from overimmunosuppression.
2021-10-04
Lacks estate sues Thermo Fisher Scientific over HeLa cells[11]Lacks estate sues Thermo Fisher Scientific over HeLa cellswbaltv.com
Reported: 2021-10-04
The estate of Henrietta Lacks sued Thermo Fisher Scientific, alleging that the company continued commercializing results derived from HeLa cells taken without Lacks' knowledge or consent. The lawsuit seeks the company's net profits from commercialization and an injunction against use of the cells without the estate's permission; the allegations are not presented as a court finding.
2021-09-15
FDA approves Oncomine Dx Target Test as a companion diagnostic for EXKIVITY[15]FDA 批准 Oncomine Dx Target Test 用于 EXKIVITY 配套诊断prnewswire.com
Reported: 2021-09-15
The FDA granted premarket approval to Thermo Fisher Scientific’s Oncomine Dx Target Test as a companion diagnostic to identify eligible patients for Takeda’s EXKIVITY therapy.
2021-08-30
Nanoscience Instruments announces Axia ChemiSEM launch[16]Nanoscience Instruments宣布推出Axia ChemiSEMprweb.com
Reported: 2021-08-31
Nanoscience Instruments announced the launch of the Axia ChemiSEM, a floor-model scanning electron microscope from Thermo Fisher Scientific.
2021-08-18
Thermo Fisher updates TaqMan mutation panel to detect Delta and Lambda[17]赛默飞更新TaqMan突变检测面板以检测德尔塔和拉姆达变异株selectscience.net
Thermo Fisher Scientific announced an update to its Applied Biosystems TaqMan SARS-CoV-2 Mutation Panel to detect the Delta and Lambda strains.
2021-07-07
Ortho Clinical Diagnostics and Thermo Fisher Scientific announce distribution agreement[18]Ortho Clinical Diagnostics与Thermo Fisher Scientific宣布分销协议prnewswire.com
Reported: 2021-07-07
Ortho Clinical Diagnostics announced a distribution agreement with Thermo Fisher Scientific to provide and support MAS Quality Controls and LabLink xL Quality Assurance Software through Ortho's VITROS QC Solutions for VITROS System customers worldwide, with China noted as in development.
2021-06-01
Moderna enters vaccine manufacturing agreement with Thermo Fisher[19]Moderna与Thermo Fisher达成疫苗生产协议health.economictimes.indiatimes.com
Reported: 2021-06-02
Moderna said it entered into an agreement with Thermo Fisher Scientific for manufacturing and packaging its Covid-19 vaccine. Thermo Fisher's Greenville, North Carolina site will provide fill/finish manufacturing services and packaging for hundreds of millions of doses.
Unconfirmed
PROGEN signed a distribution agreement with Thermo Fisher Scientific[20]PROGEN 与 Thermo Fisher Scientific 签署分销协议prnewswire.com
Reported: 2021-04-29
PROGEN signed a non-exclusive distribution agreement with Thermo Fisher Scientific for selected proprietary antibodies. Thermo Fisher will offer 371 of PROGEN's primary antibodies globally.

Showing the 10 most recent.